文献速递免疫规划卫生政策与健康促进

重组与标准剂量流感疫苗对流感相关住院的疫苗效果:一项回顾性检测阴性设计研究

Vaccine effectiveness of recombinant and standard dose influenza vaccines against influenza related hospitalization using a retrospective test-negative design.
PubMed 文献 · Vaccine · 2023-07-18

该研究采用回顾性检测阴性设计,纳入美国大型医疗系统19家医院2018-2019和2019-2020季节住院并接受RT-PCR流感检测的18-64岁及≥65岁成人,比较重组流感疫苗(RIV4)与标准剂量疫苗(SD-IIV4)对流感住院的相对疫苗效果(rVE)。主要分析纳入14,590人,其中RIV4接种3,338人、SD-IIV4接种976人、未接种10,276人。经倾向评分逆概率加权调整后,RIV4总体rVE为31(95%CI 11%,46%),在18-64岁成人中rVE为29(95%CI 4%,47%)。

要点

  • RIV4总体相对疫苗效果显著,rVE=31(95%CI 11%,46%)。
  • 18-64岁成人中RIV4相对疫苗效果显著,rVE=29(95%CI 4%,47%)。
  • RIV4在女性、年轻成人及无高危条件者中较SD-IIV4提供更好保护。

核心结论

  • 在所有成人中,RIV4和SD-IIV4对流感住院均有效,RIV4总体上、在女性、年轻成人及无高危条件者中较SD-IIV4提供更好保护。

研究设计与样本

  • 研究为回顾性检测阴性病例对照研究,使用电子数据库。
  • 纳入2018-2019和2019-2020季节在美国大型医疗系统(19家医院)住院且临床接受RT-PCR流感检测的18-64岁及≥65岁成人。
  • 通过医院电子病历和州免疫登记确认流感疫苗接种。
  • 采用倾向评分逆概率加权调整潜在混杂因素并确定rVE。
  • 主要分析纳入14,590人,其中RIV4接种3,338人、SD-IIV4接种976人、未接种10,276人。

主要发现

  • 经倾向评分逆概率加权调整后,RIV4总体rVE为31(95%CI 11%,46%)。
  • 在18-64岁年轻成人中,RIV4总体rVE为29(95%CI 4%,47%)。
  • 大多数参与者为白人(80%),70%有高危条件,女性略过半(54%),65岁及以上者占53%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Relative effectiveness of various vaccine formulations provide important input for vaccine policy decisions and provider purchasing decisions. We used electronic databases to conduct a test-negative case control study to determine relative vaccine effectiveness (rVE) of recombinant influenza vaccine (RIV4) compared with standard dose vaccines (SD-IIV4) against influenza hospitalization. METHODS: Adults 18-64 and ≥65 years of age hospitalized in a large U.S. health system (19 hospitals) in 2018-2019 and 2019-2020 who were clinically tested for influenza using reverse transcription polymerase chain reaction (RT-PCR) assays were included. The hospital system electronic medical record (EMR) and the state immunization registry were used to confirm influenza vaccination. Propensity scores with inverse probability weighting were used to adjust for potential confounders and determine rVE. RESULTS: Of the 14,590 individuals included in the primary analysis, 3,338 were vaccinated with RIV4 and 976 were vaccinated with SD-IIV4, with the balance of 10,276 being unvaccinated. Most participants were white (80 %), most (70 %) had a high-risk condition, just over half were female (54 %) and age 65 years or older (53 %). Overall RIV4 rVE was significant when adjusted for propensity scores with inverse probability weights (rVE = 31; 95 % CI = 11 %, 46 %). Among younger adults (18-64 years-old), overall rVE of RIV4 was significant (rVE = 29; 95 % CI = 4 %, 47 %). CONCLUSIONS: Over all adults, both RIV4 and SD-IIV4 were effective against influenza hospitalization, with RIV4 providing better protection compared with SD-IIV4 overall, for females, younger adults, and those with no high-risk conditions.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zimmerman RK, Patricia Nowalk M, Dauer K, et al. Vaccine effectiveness of recombinant and standard dose influenza vaccines against influenza related hospitalization using a retrospective test-negative design. Vaccine. 2023. PMID: 37474406. doi:10.1016/j.vaccine.2023.06.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。